Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign-up

Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes

Evidence related to diabetic kidney disease

Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.

Build your Evidence Workspace

Save evidence about the topics you care about.

9
Studies
15
Evidence Pairs
Moderate Research Support
Relationship Confidence: 62/100

Evidence summary for AI and search

Among 9 indexed studies and 7 interventions, the strongest signals are summarized from deterministic graph patterns. Dapagliflozin appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

9

Research documents analyzed

Evidence Pairs

15

Intervention-outcome relationships

Latest Publication

Jun 2026
Powered by the Dediabetes Evidence Intelligence™ framework

Evidence Snapshot

Qualitative overview of the evidence landscape

Low Confidence

Based on 9 studies, moderate evidence suggests Empagliflozin, Finerenone (nonsteroidal mineralocorticoid receptor antagonist), Metformin are the strongest-supported interventions for diabetic kidney disease.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

9
Studies
7
Interventions
7
Outcomes
0
Strong evidence signals
0
Mixed evidence areas
Evidence freshness
Jun 2026
Latest indexed
Evidence Story

Diabetic Kidney Disease evidence appears to center on Dapagliflozin.

Among 9 indexed studies and 7 interventions, the strongest signals are summarized from deterministic graph patterns. Dapagliflozin appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Dapagliflozin appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 4 evidence pairs - 3 studies

Why this appears here

Moderate evidenceConsistent resultsPositive effect signalMultiple studies
Dapagliflozin
3 studies
EvidenceScore™
63/100
ConsistencyScore™
71/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Dapagliflozin is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Dapagliflozin
Empagliflozin
Dapagliflozin
3 studies
EvidenceScore™
63/100
ConsistencyScore™
71/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present
Evidence basis: 12 evidence pairs - 7 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Dapagliflozin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Dapagliflozin
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Dapagliflozin
3 studies
EvidenceScore™
63/100
ConsistencyScore™
71/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength
Evidence basis: 10 evidence pairs - 6 studies
View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

Does Dapagliflozin improve urinary albumin-to-creatinine ratio?

intervention effectiveness
Moderate Evidence

Dapagliflozin may improve Urinary albumin-to-creatinine ratio.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Dapagliflozin

    EvidenceScore™ Moderate | EvidenceScore™ 63.1 | moderate positive | ConsistencyScore™ Consistent | 2 studies

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

  • Only a small number of supporting studies are available.
  • Population details are unavailable.
2 supporting studies1 RCTUpdated: Jul 2026

Does SGLT2 inhibitors improve albuminuria?

intervention effectiveness
Emerging Evidence

SGLT2 inhibitors appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    SGLT2 inhibitors

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Does Empagliflozin improve urinary albumin-to-creatinine ratio?

intervention effectiveness
Emerging Evidence

Current evidence does not show a clear benefit of Empagliflozin for Urinary albumin-to-creatinine ratio.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Empagliflozin

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve albuminuria?

intervention effectiveness
Emerging Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 systematic reviewLatest publication: May 2026Updated: Jul 2026

Does Dapagliflozin improve estimated glomerular filtration rate?

intervention effectiveness
Emerging Evidence

Dapagliflozin appears to improve Estimated glomerular filtration rate.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Dapagliflozin

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve composite renal outcomes (kidney failure, sustained egfr decline ≥57%, renal death)?

intervention effectiveness
Emerging Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 systematic reviewLatest publication: May 2026Updated: Jul 2026

Does SGLT2 inhibitors reduce renal and urinary disorders incidence?

intervention effectiveness
Emerging Evidence

Current evidence does not show a clear benefit of SGLT2 inhibitors for Renal and urinary disorders incidence.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    SGLT2 inhibitors

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Does Pentoxifylline improve albuminuria?

intervention effectiveness
Emerging Evidence

Pentoxifylline appears to improve Albuminuria.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Pentoxifylline

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTLatest publication: Jun 2026Updated: Jul 2026

Studied interventions

Interventions studied in relation to this topic

Empagliflozin

1 study
View evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

1 study
View evidence

Metformin

1 study
View evidence

Pentoxifylline

1 study
View evidence

SGLT2 inhibitors

1 study
View evidence

Dapagliflozin

2 studies
View evidence

Integrated multidisciplinary diabetes and kidney care program

1 study
View evidence

Note: ImpactScore™, EvidenceScore™, and ConsistencyScore™ values are provided by the Evidence Intelligence™ read model when available. Click any option to explore the supporting research in our archive.

Strongest evidence signals

Key patterns and insights identified across the research landscape

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Moderate positive signal

Dapagliflozin may improve Urinary albumin-to-creatinine ratio

Dapagliflozin → Urinary albumin-to-creatinine ratio

Across 2 studies, Dapagliflozin shows a consistent moderate positive signal for Urinary albumin-to-creatinine ratio.

2 studies
EvidenceScore™: 63.07692307692308/100
View supporting studies
Strong positive signal

Dapagliflozin shows strong evidence for improving Estimated glomerular filtration rate

Dapagliflozin → Estimated glomerular filtration rate

Across 1 study, Dapagliflozin shows a strong positive signal for Estimated glomerular filtration rate.

1 studies
EvidenceScore™: 59/100
View supporting studies
Strong positive signal

Dapagliflozin shows strong evidence for improving Renal and urinary disorders incidence

Dapagliflozin → Renal and urinary disorders incidence

Across 1 study, Dapagliflozin shows a strong positive signal for Renal and urinary disorders incidence.

1 studies
EvidenceScore™: 59/100
View supporting studies
Neutral signal

Empagliflozin shows limited or neutral effect on Urinary albumin-to-creatinine ratio

Empagliflozin → Urinary albumin-to-creatinine ratio

Across 1 study, Empagliflozin shows a neutral signal for Urinary albumin-to-creatinine ratio.

1 studies
EvidenceScore™: 59/100
View supporting studies
Evidence signal

Empagliflozin shows evidence for Urinary L-FABP

Empagliflozin → Urinary L-FABP

Across 1 study, Empagliflozin shows a evidence signal for Urinary L-FABP.

1 studies
EvidenceScore™: 59/100
View supporting studies

Supporting Research

Selected studies that best represent the evidence behind this topic.

Click any study to view the full research summary, or click interventions and outcomes to filter the archive.

Related Evidence Topics

Explore related evidence areas connected by shared studies, interventions, or outcomes.

SGLT2 Inhibitors

Intervention

Related because they study similar interventions

5 shared studies

Adverse Events and Safety

Mixed

Related because they study similar interventions

2 shared studies

Evidence Tracker

Track Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes evidence

Save this evidence topic and revisit it as new studies are added.